Table 2. Adverse events in ≥ 2 patients in the exploratory phase II trial.
| 30 mg cohort (n = 9) |
50 mg cohort (n = 10) |
All (n = 19) |
||||
|---|---|---|---|---|---|---|
| Event | Total (%) | ≥ Grade 3 (%) | Total (%) | ≥ Grade 3 (%) | Total (%) | ≥ Grade 3 (%) |
| Thrombocytopenia | 3 (33.3) | 2 (22.2) | 6 (60.0) | 4 (40.0) | 9 (47.4) | 6 (31.6) |
| Leucopenia | 1 (11.1) | 1 (11.1) | 4 (40.0) | 1 (10.0) | 5 (26.3) | 2 (10.5) |
| Fever | 1 (11.1) | 0 | 3 (30.0) | 0 | 4 (21.1) | 0 |
| Fatigue | 0 | 0 | 3 (30.0) | 0 | 3 (15.8) | 0 |
| Anemia | 1 (11.1) | 1 (11.1) | 1 (10.0) | 0 | 2 (10.5) | 1 (5.3) |
| Nausea | 0 | 0 | 2 (20.0) | 0 | 2 (10.5) | 0 |